



META KING

A SUBSTITUTE FOR NICOTINE

Introduction of (S)-6-methyl nicotine

Presented by: GM2 Manufacturing

WHAT IS (S)-6-METHYL NICOTINE ?

Appearance


It is a colorless and transparent liquid which has similar physical and chemical properties to nicotine

Source

It is an unnatural product produced by chemical and biological synthesis, Tobacco free

Features

It is a Nicotine structural analogues that have better pharmacological action and lower toxicity.



CAS No:13270-56

WHY DO WE CHOOSE [S]-6-METHYL NICOTINE AS A SUBSTITUTE?



Compare to nicotine

- 01 Better pharmacological activity ensures a better product experience at lower doses
- 02 Low toxicity ensures the safety of customers' products using
- 03 Its similar physicochemical properties to nicotine ensures its application without any limitation as nicotine substitute

PREDICTED PHYSICOCHEMICAL PROPERTIES COMPARISON

PREDICTED AVERAGE VALUES

Physicochemical Property	(S)-6-Methyl Nicotine	(S)-Nicotine
Physical State	Liquid	Liquid
Melting Point (°C)	20.9	18.1
Boiling Point (°C)	259	246
Density (g/cm ³)	1.01	1.03
Vapor pressure (mm Hg)	7.30×10^{-3}	2.39×10^{-2}
Partition coefficient, log Kow	1.42	0.928
Solubility in water (mol/L)	0.849	2.18
Surface tension (dyn/cm)	37.4	38
Flash point (°C)	112	98.6
Viscosity (cP)	11.8	7.28



AEROSOL TRANSFER

EFFICIENCY COMPARISON

"NICOTINE" CONC. (MG/G)

Form	Active Agent	E-Liquid	Aerosol	Transfer Efficiency (%)
Freebase	(S)-Nicotine	43.0±0.0	36.8±1.2	85.6±2.9
	(S)-6-Methyl-Nicotine	41.5±0.1	34.2±0.2	82.5±0.6
Benzoate	(S)-Nicotine	40.4±0.1	36.4±0.8	90.2±2.1
	(S)-6-Methyl-Nicotine	42.3±0.1	37.4±2.0	88.3±4.6

Aerosol transfer efficiency comparison between (S)-6-Methyl Nicotine and (S)-Nicotine. Values are average ± standard deviation(n=3).

RELATIVE AFFINITY AND POTENCY OF (S)-6-METHYLNICOTINE COMPARED TO (S)-NICOTINE

Affinity Experiments (Rat Model)

Brain
Nic
ACh-Ki(relative)
nAChRradioligand binding (rat brain)

Relative Affinity
(Higher = stronger)

8.33
0.38
0.08
0.70

Ref.

1
1
1
2

Functional Experiments

LD50 (mice)
ED50 (mice; effect: convulsions)
Model 03 Guinea Pig Ileum
Model 05 Rat Phrenic Nerve-Diaphragm
Model 06 Guinea Pig Auricle
Model 09 Rabbit Aortic Strip
Blood Pressure (Increase by 25%)
Drug Discrimination
Prostration

Relative Potency
(Higher = more potent)

2.61
2.62
1.96
0.46
1.47
1.10
0.42
1.09-2.19
1.08

Ref.


1
1
3
3
3
4
1
1

**However, caution should be taken since these studies are not
pe-reviewed and used potentially outdated methodologies**

Reference:

1. INBIFO, <https://www.industrydocuments.ucsf.edu/docs/gscv0119>
2. Dukat, M., et al., *Bioorg. Med. Chem. Lett*, 2002, 12(20), 3005-3007
3. INBIFO, <https://www.industrydocuments.ucsf.edu/docs/prjb0115>
4. INBIFO, <https://www.industrydocuments.ucsf.edu/docs/mnjw0118>


CYTOTOXICITY-NEUTRAL RED UPTAKE (NRU) RESULTS



Dosing 0.08 to 5mg.mL and cell incubated for 48hrs, No substantial cytotoxicity observed and IC50 values could not be determined for either formulation.

Neutral Red Uptake (NRU) Results for 6-MeN and Nic e-liquid formulations (n=9)

MUTAGENICITY-AMES TEST RESULTS



Dosing 0 5000µg/plate; ncubated for 48-72h.

No dose-response behavior observed in any test strain for both agents.


Revertant formation is comparable to the vehicle control (0µg/mL dosage) at all doses.

Both 6MeN and Nic show no mutagenic activity.

Ames test results for 6MeN (left) and Nic (right) e-liquid formulations (n=6).

GENOTOXICITY-IN VITRO

MICRO NUCLEUS (MN) TEST RESULTS



In vitro Micro nucleus (MN) test results for 6MeN (left) and Nic (right) e-liquid formulations (n=4)

Identifies agents that induce cytogenetic damage via the observation of micro nuclei in daughter cells.

TK6 cells treated with serial dilutions (7200 to 847 µg/mL e-liquid) under three conditions:

Revertant formation is comparable to the vehicle control (0µg/mL dosage) at all doses

- Schedule (i): short term (4h) with no metabolic activation.
- Schedule (ii): short term (4h) with metabolic activation.
- Schedule (iii): long-term (22h) with no metabolic activation

• Both formulations were determined to be negative for genotoxicity under all conditions.

SUMMARY

- (S)-6-methyl nicotine has similar chemical characteristics to (S)-nicotine and behaves similarly under different testing conditions.
- In silico toxicological and historical pharmacological studies suggest some what comparable activity.
- 6-methyl nicotine exhibits comparable toxicological behaviour to (S)-nicotine with no mutagenic or genotoxic activity and limited cytotoxicity.
- Initial experiments suggest (S)-6-methyl nicotine could be a suitable replacement for (S)-Nicotine.

BUT WHY CHOOSE OUR (S)-6-METHYL NICOTINE?



Stable and
repeatable process



Different forms
of product



High Quality



Global service
support

DIFFERENCE OF OUR PROCESS

Process validation

Based on QbD, risk assessments were conducted for all of process parameter, and commercial process verification was carried out to prove that its good process repeatability and stability.

Construction of chiral center

Apply the green synthetic biology techniques, Construct the chiral center by enzyme to control the level of enantiomer less than 0.15%

Long-term stability study

Product quality, packaging and storage conditions have been verified by long term studies.

Product quality inspection

All analytical methods were validated based on ICH guidelines, the validation of analytical methods and the batch release carried out in the GLP lab.

Quality assurance

The whole quality management is implemented under GMP conditions.



OUR QUALITY SYSTEM

To: regaffairs@fda.hk
 From: 812024 1212
 Re: regaffairs@fda.hk
 Subject: HUMAN MESSAGE BATTERY/EMSA-FM740201-Ready to Use
 Pharmaceutical (N) 18172008

Dear Sir,
 Beijing Government Department of Health
 Room 100000000000
 Beijing, P.R. China
 Tel: 86 10 123456789

The U.S. Food and Drug Administration (FDA) conducted an inspection at Beijing Government Department of Health, P.R. China, on 12/12/2012. The inspection was conducted in accordance with the provisions of the United States Food and Drug Administration (FDA) Code of Federal Regulations (CFR) 21.312. The inspection was conducted in accordance with the provisions of the United States Food and Drug Administration (FDA) Code of Federal Regulations (CFR) 21.312. The inspection was conducted in accordance with the provisions of the United States Food and Drug Administration (FDA) Code of Federal Regulations (CFR) 21.312.

The inspection was conducted in accordance with the provisions of the United States Food and Drug Administration (FDA) Code of Federal Regulations (CFR) 21.312.

The inspection was conducted in accordance with the provisions of the United States Food and Drug Administration (FDA) Code of Federal Regulations (CFR) 21.312.

The inspection was conducted in accordance with the provisions of the United States Food and Drug Administration (FDA) Code of Federal Regulations (CFR) 21.312.

The inspection was conducted in accordance with the provisions of the United States Food and Drug Administration (FDA) Code of Federal Regulations (CFR) 21.312.

The inspection was conducted in accordance with the provisions of the United States Food and Drug Administration (FDA) Code of Federal Regulations (CFR) 21.312.

The inspection was conducted in accordance with the provisions of the United States Food and Drug Administration (FDA) Code of Federal Regulations (CFR) 21.312.



附件
 07080206 (1.21P)

Medicines and Healthcare Products Regulatory Agency CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1
 (Issued subject to the provisions of sub-section 2(1) of Section 200(1)(b) of the Medicines Act 1968)
 The compliance certificate is issued to the manufacturer of the following medicinal products:
 (The names of the medicinal products are listed in Part 2 of this certificate)
 The certificate is issued to the manufacturer of the following medicinal products:
 (The names of the medicinal products are listed in Part 2 of this certificate)

The certificate is issued to the manufacturer of the following medicinal products:
 (The names of the medicinal products are listed in Part 2 of this certificate)
 The certificate is issued to the manufacturer of the following medicinal products:
 (The names of the medicinal products are listed in Part 2 of this certificate)

The certificate is issued to the manufacturer of the following medicinal products:
 (The names of the medicinal products are listed in Part 2 of this certificate)

北京市药品监督管理局

北京市药品监督管理局 药品 GMP 符合性检查 结果通知书

编号: (京) 2012070208

根据《中华人民共和国药品管理法》等法律法规的规定,
 北京市药品监督管理局对贵单位的药品生产进行了检查。

检查结果可以概括为: 符合 GMP 要求。

企业名称: 北京红杉生物制药有限公司

注册地址: 北京市顺义区北坛镇中北工业园内

生产地址和生产范围: 北京市顺义区北坛镇中北工业园内; 其他: 大葆台法林村, 魏各庄村, 李干村等村。小葆台法林村(魏各庄村、李干村等村), 口福村等村, 魏各庄村等村。

检查地址: 北京市顺义区北坛镇中北工业园内

检查日期: 2012年1月16日至17日

生产范围: 小葆台法林村(魏各庄村、李干村等村)

生产范围: 小葆台法林村(魏各庄村、李干村等村)

生产范围: 小葆台法林村(魏各庄村、李干村等村)

生产范围: 小葆台法林村(魏各庄村、李干村等村)

附件: 药品 GMP 符合性检查报告

附件: 药品 GMP 符合性检查报告



NMPA, FDA and EP audience certification

